X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EO-3021 (SYSA1801) is an antibody drug conjugate that targets Claudin 18.2. It is being evaluated for advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic or esophageal cancers.
Lead Product(s): EO-3021
Therapeutic Area: Oncology Product Name: SYSA1801
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
EO-3021 is a potential best-in-class antibody-drug conjugate that targets Claudin 18.2 evaluating patients with advanced unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers.
Lead Product(s): EO-3021
Therapeutic Area: Oncology Product Name: EO-3021
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
Under the terms of the agreement, Elevation Oncology will develop and commercialize EO-3021 in all global territories outside of Greater China. EO-3021 (also known as SYSA1801) is a differentiated, clinical stage antibody drug conjugate that targets Claudin18.2.
Lead Product(s): SYSA1801
Therapeutic Area: Oncology Product Name: EO-3021
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: CSPC Pharmaceutical Group
Deal Size: $1,175.0 million Upfront Cash: $27.0 million
Deal Type: Licensing Agreement July 28, 2022
Details:
The response rate observed in Cohort 1 patient population, including complete and partial responses, together with early signs of durable responses and a well-tolerated safety profile, demonstrate the potential of MM-121 (seribantumab) to become a best-in-class therapy.
Lead Product(s): Seribantumab
Therapeutic Area: Oncology Product Name: MM-121
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3). HER3 is traditionally activated through binding of its primary ligand, neuregulin-1 (NRG1).
Lead Product(s): Seribantumab
Therapeutic Area: Oncology Product Name: MM-121
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
As of the data, treatment with seribantumab resulted in durable clinical benefit for over 9 months, an approximately 90% reduction in the cancer biomarker CA19-9, and an ongoing 3 month confirmed partial response per RECIST criteria with a maximum tumor reduction of over 50%.
Lead Product(s): Seribantumab
Therapeutic Area: Oncology Product Name: MM-121
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Details:
Seribantumab demonstrates significant activity in preclinical models through the destabilization of HER3 the & entire ERBB signaling pathway. These results are now being clinically evaluated in the PhII CRESTONE study for solid tumor patients harboring an NRG1 gene fusion.
Lead Product(s): Seribantumab
Therapeutic Area: Oncology Product Name: MM-121
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Under this collaboration Elevation Oncology will utilize US Oncology Research Selected Trials for Accelerated Rollout program for patient enrollment in the registration-enabling Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.
Lead Product(s): Seribantumab
Therapeutic Area: Oncology Product Name: MM-121
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: US Oncology Network
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 30, 2020
Details:
Company to initiate a Phase 2 CRESTONE study, and new partnerships with Next Generation Sequencing diagnostic providers to explore innovative models for real-time identification, patient referral, and enrollment of patients with tumors driven by rare genomic alterations.
Lead Product(s): Seribantumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aisling Capital
Deal Size: $32.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
